Bio-Matrix Scientific Receives Certificate of Compliance for Class 10,000 Processing Laboratory.SAN DIEGO -- Bio-Matrix Scientific Group Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :BMSN BMSN Seaman, Boatswain's Mate Striker (Naval Rating) ), a biotechnology company focused on stem cell stem cell In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult. cryogenics cryogenics: see low-temperature physics. cryogenics Study and use of low-temperature phenomena. The cryogenic temperature range is from −238°F (−150°C) to absolute zero. At low temperatures, matter has unusual properties. and disposable stem cell/tissue transfer instruments, announced today it has received its Certificate of Compliance for the new Stem Cell Class 10,000 Processing Laboratory. The certificate has been granted by the Controlled Environmental Regulatory Testing Services (CERTS), which conducts ISO (1) See ISO speed. (2) (International Organization for Standardization, Geneva, Switzerland, www.iso.ch) An organization that sets international standards, founded in 1946. The U.S. member body is ANSI. certification testing. Bio-Matrix Scientific has completed the calibration and certification of the class 10,000 clean room and has received the ISO 14644 class 7 certificate of compliance. Bio-Matrix's stem cell processing laboratory now meets Federal Air Control Regulations to operate as a Class 10,000 Clean Room. Bio-Matrix intends to utilize state-of-the art closed processing systems to harvest stem cells in its cord blood division by obtaining stem cells from fat tissue, which is a new dimension of stem cell banking. This processing system requires several procedures that must be carried out under strictly controlled environments to minimize the risk of microbial microbial pertaining to or emanating from a microbe. microbial digestion the breakdown of organic material, especially feedstuffs, by microbial organisms. contamination. Bio-Matrix Chairman & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. David Koos stated, "This certificate of compliance, which forms part of our comprehensive cGMP (good manufacturing practices) and cGTP (good tissue practices) systems, will assure our customers that their stem cells are processed and stored under safe, controlled environments." Bio-Matrix's new 15,000-sq-ft, state-of-the-art laboratory, located in the heart of the San Diego biotechnology corridor, will house Bio-Matrix's secure Cryogenic Stem Cell Bank; three research laboratories; an aseptic aseptic /asep·tic/ (-tik) free from infection or septic material. a·sep·tic adj. Of, relating to, or characterized by asepsis. cellular/tissue class 10,000/100 processing laboratory; and hematology, microbiology and flow cytometry laboratories. This press release is available on the company's official online Investor Relations HUB at http://www.agoracom.com/IR/Bio-Matrix for investor questions, answers and monitored commentary. Alternatively, investors are able to e-mail all questions and correspondence to BMSN@agoracom.com, where they can also request addition to the investor e-mail list to receive all future press releases and updates in real time. About Bio-Matrix Scientific Group Inc. Bio-Matrix Scientific Group Inc. (www.BMSNonline.com) is a biotech research and development Company that commercializes medical devices and monitoring systems for the growing, worldwide stem cell research market. The Company aligns itself with strategic partners that offer key technologies in biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. device development, tissue engineering, cell culturing, genome therapy and drug delivery systems to become a leading source for stem cell research technology and innovation and is building a state-of-the-art facility in San Diego to cater to the growing stem cell research segment of the $75 billion biotechnology and medical device industry. DISCLAIMER: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion